<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9301">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05700916</url>
  </required_header>
  <id_info>
    <org_study_id>H22-0161</org_study_id>
    <nct_id>NCT05700916</nct_id>
  </id_info>
  <brief_title>Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity</brief_title>
  <official_title>Evaluation of Milk Polar Lipids on Lipoprotein Metabolism, Inflammation, and Gut Microbiota in Dyslipidemic Adults With Abdominal Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dairy Management Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Connecticut</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major objective of this project is to examine whether daily consumption of milk polar&#xD;
      lipids (MPLs) influences cardiometabolic risk factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a randomized, double-blind, controlled, parallel, intervention&#xD;
      study in dyslipidemic adults with abdominal obesity (n = 130). Participants will consume&#xD;
      either a control dairy beverage (n = 65) or an MPL-rich dairy beverage (n = 65) for 8 weeks.&#xD;
      The investigators plan to evaluate the following 4 specific objectives:&#xD;
&#xD;
        1. Determine the effects of MPLs on serum lipid concentrations and other cardiometabolic&#xD;
           risk factors.&#xD;
&#xD;
        2. Evaluate the effects of MPLs on systemic biomarkers of low-grade inflammation.&#xD;
&#xD;
        3. Examine the effects of MPLs on lipoprotein metabolism and lipoprotein particle&#xD;
           characteristics.&#xD;
&#xD;
        4. Evaluate the effects of MPLs on gut microbiota, gut permeability markers, and fecal&#xD;
           lipids.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2023</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Serum LDL Cholesterol at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurement of serum LDL cholesterol (mg/dL) at the beginning and end of 8-week intervention arm.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>MPL-rich dairy powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily consumption of 50 g of dairy powder containing 6.5 g MPL for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control dairy powder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily consumption of 50 g of dairy powder containing &lt;0.1 g MPL for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milk Polar Lipid-Rich Dairy Powder</intervention_name>
    <description>Effects of the addition of 6.5 g of milk polar lipids to dairy powder.</description>
    <arm_group_label>MPL-rich dairy powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dairy Powder</intervention_name>
    <description>Effects of dairy control powder</description>
    <arm_group_label>Control dairy powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  LDL-C ≥ 130 mg/dL&#xD;
&#xD;
          -  Waist circumference ≥ 88 cm for women, ≥ 102 cm for men&#xD;
&#xD;
          -  Aged 40 to 70 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Heart disease&#xD;
&#xD;
          -  Stroke&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Eating disorders&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  Gut-associated pathologies&#xD;
&#xD;
          -  Autoimmune diseases&#xD;
&#xD;
          -  Chronic inflammatory diseases&#xD;
&#xD;
          -  Scleroderma&#xD;
&#xD;
          -  Gallbladder disease&#xD;
&#xD;
          -  Blood clotting disorders&#xD;
&#xD;
          -  Intravenous drug use&#xD;
&#xD;
          -  Self-reported pre-menopausal status&#xD;
&#xD;
          -  Fasting plasma/serum triglycerides &gt;500 mg/dL&#xD;
&#xD;
          -  Fasting plasma/serum glucose &gt;126 mg/d&#xD;
&#xD;
          -  Weight changes &gt;10% over last 4 weeks&#xD;
&#xD;
          -  Oral antibiotics use up to 1 month prior to and during study&#xD;
&#xD;
          -  Allergy or intolerance to milk products&#xD;
&#xD;
          -  Taking lipid-lowering medications (e.g., statins, fibrates)&#xD;
&#xD;
          -  Taking anti-inflammatory medications (e.g., corticosteroids)&#xD;
&#xD;
          -  Taking medications which primarily affect blood clotting (e.g., warfarin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher N Blesso, Ph.D.</last_name>
    <phone>860-486-9049</phone>
    <email>christopher.blesso@uconn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Connecticut</name>
      <address>
        <city>Storrs</city>
        <state>Connecticut</state>
        <zip>06269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Connecticut</investigator_affiliation>
    <investigator_full_name>Christopher Blesso</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

